Top Page
China NT Pharma Group Co., Ltd.
(1011)
China NT Pharma Group Co., Ltd. (1011) vs. iShares MSCI Hong Kong ETF (EWH)
China NT Pharma Group Co., Ltd. Business Overview & Revenue Model
China NT Pharma Group Co., Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 37.96M | 7.37M | 207.09M | 226.70M | 221.73M |
| Gross Profit | 5.26M | 7.37M | 125.29M | 145.46M | 134.90M |
| EBITDA | -8.65M | 1.33M | 10.39M | -17.78M | -43.74M |
| Net Income | -53.36M | -143.59M | -66.41M | -151.33M | -191.27M |
Balance Sheet | |||||
| Total Assets | 334.07M | 329.12M | 1.01B | 955.36M | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 9.62M | 1.52M | 5.93M | 9.44M | 7.69M |
| Total Debt | 375.95M | 344.94M | 826.45M | 832.11M | 851.46M |
| Total Liabilities | 733.18M | 668.69M | 1.25B | 1.17B | 1.27B |
| Stockholders Equity | -399.11M | -339.56M | -241.66M | -211.38M | 16.28M |
Cash Flow | |||||
| Free Cash Flow | -9.24M | 37.58M | 31.72M | -135.42M | 2.36M |
| Operating Cash Flow | -9.07M | 50.48M | 36.21M | -134.78M | 26.20M |
| Investing Cash Flow | -189.00K | -22.14M | 4.53M | 257.81M | 595.60M |
| Financing Cash Flow | 12.65M | -28.97M | -46.68M | -124.80M | -624.25M |
China NT Pharma Group Co., Ltd. Technical Analysis
China NT Pharma Group Co., Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$295.33M | 10.86 | 2.72% | 3.05% | -4.17% | -1.83% | |
60 Neutral | HK$15.31B | 5.72 | -7.43% | 4.61% | 11.60% | -21.06% | |
55 Neutral | HK$343.16M | 48.41 | 0.55% | 9.84% | -66.75% | -83.83% | |
52 Neutral | HK$197.69M | ― | -7.93% | ― | 1.13% | 38.41% | |
49 Neutral | HK$279.38M | ― | -40.39% | ― | -43.73% | -434.56% | |
48 Neutral | HK$310.15M | ― | ― | ― | ― |
China NT Pharma Group Co., Ltd. Corporate Events
China NT Pharma Group Co., Ltd. announced a delay in the dispatch of a circular related to its acquisition of 100% of the issued shares in certain target companies. The circular, which includes details of the Sale and Purchase Agreement and other required information, was initially expected to be sent to shareholders by June 30, 2025, but will now be postponed to on or before October 31, 2025. This delay may impact the timeline for the acquisition process and could have implications for stakeholders awaiting further details.
China NT Pharma Group Co., Ltd. announced that all resolutions proposed at their Annual General Meeting (AGM) held on June 30, 2025, were passed by shareholders. The resolutions included the adoption of financial statements, re-election of directors, appointment of auditors, and granting of mandates related to share issuance and repurchase. This successful AGM reflects strong shareholder support and positions the company for continued operational stability and strategic growth.
China NT Pharma Group Co., Ltd. has announced the composition of its board of directors, which includes a mix of executive, non-executive, and independent non-executive directors. The announcement also details the membership of the board committees, which is crucial for stakeholders to understand the governance structure and decision-making processes within the company.
China NT Pharma Group Co., Ltd. has announced changes to its Board Committee, appointing Dr. Zhao Yubiao as Chairman of the Nomination Committee and Ms. Ng Anna Ching Mei as a member, while Mr. Ng Tit has stepped down as Chairman. These changes are effective immediately following the Board’s approval. This restructuring of the Nomination Committee may impact the company’s governance and strategic direction, potentially influencing its decision-making processes and stakeholder engagement.
China NT Pharma Group Co., Ltd. has revised and adopted the terms of reference for its Nomination Committee, which is responsible for overseeing the structure and composition of the Board of Directors. The Nomination Committee will consist of at least two independent non-executive directors and will focus on board diversity, succession planning, and the assessment of director independence. This move aims to enhance corporate governance and align the board’s composition with the company’s strategic goals.
China NT Pharma Group Co., Ltd. has announced a change in its executive leadership with Mr. Ng Tit stepping down as CEO to focus on strategic development, while remaining as Chairman of the Board. Mr. Zhang Bozhi, an experienced professional in the pharmaceutical industry with a background in sales and management, has been appointed as the new CEO, bringing his expertise to drive the company’s business development and strategic planning.
China NT Pharma Group Co., Ltd. has announced a potential acquisition and disposal involving its associate, Beijing Kangchen Biotechnology Company Limited. The proposed plan involves splitting the assets of the associate to protect shareholder interests, with the intention of dissolving the associate relationship and allowing independent operations. This move could impact the company’s operations by potentially expanding its asset base and altering its industry positioning, depending on the outcome of negotiations with Konruns Pharmaceutical.
China NT Pharma Group Co., Ltd. announced the successful completion of a profit guarantee related to its associate, Beijing Kangchen Biotechnology Company Limited. The profit guarantee, which was part of a larger acquisition agreement with Beijing Konruns Pharmaceutical Company Limited, required the associate’s Miacalcic business to achieve specific net profit targets from 2021 to 2023. The associate exceeded these targets each year, signaling strong performance and potentially enhancing NT Pharma’s industry positioning and stakeholder confidence.
China NT Pharma Group Co., Ltd. has announced its Annual General Meeting (AGM) scheduled for June 30, 2025, in Hong Kong. Key agenda items include the adoption of financial statements, re-election of directors, and re-appointment of auditors. The company also seeks shareholder approval to authorize the board to issue additional shares, reflecting its strategic focus on growth and capital management. This move could potentially impact the company’s market positioning and shareholder value.
China NT Pharma Group Co., Ltd. has issued a clarification regarding its acquisition of 100% of the issued shares in target companies, involving the issuance of consideration shares under a specific mandate. The company corrected financial figures for its PRC Operating Company for the years ending December 2023 and 2024, stating that the figures should be in RMB rather than thousands of RMB. This clarification ensures accurate financial reporting, which is crucial for stakeholders assessing the company’s financial health and strategic acquisitions.
China NT Pharma Group Co., Ltd. has announced a major transaction involving the acquisition of 100% of the issued shares in certain target companies. The acquisition, valued at approximately RMB116.2 million, will be financed through the issuance of consideration shares under a specific mandate, pending shareholder approval. This move is classified as a major transaction under the Hong Kong Stock Exchange’s listing rules, necessitating reporting and shareholder approval. The acquisition aims to expand the company’s operational scope, although its completion is contingent upon meeting certain conditions.